PMS2 and colorectal carcinoma: We found that the majority (72.1%) of cases of EO-CRC showed intact expression for MSI markers, whereas 13.2% of cases showed loss of expression of all markers, and 13.2% revealed combined loss of expression for MLH1 and PMS2.